In a move to bolster its offerings of rare disease treatments, Johnson & Johnson announced on Jan. 26 the largest deal in its history with a proposed $30 billion buy of Swiss biotechnology company Actelion Ltd.

The all-cash deal gives the world’s largest health care company access to Actelion’s lucrative medications for high blood pressure, pulmonary arterial hypertension and other rare conditions.